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Large primary breast tumours and extensive lymph node involvement are linked to a high rate of local recurrence after surgery. In
10–20% of such high-risk breast cancer patients, local relapse will occur despite postoperative radiotherapy. In the present study, we
investigated whether molecular features, such as angiogenesis, cancer cell proliferation, steroid receptor expression, c-erbB-2
oncoprotein overexpression, p53 protein nuclear accumulation or bcl-2 antiapoptotic protein expression, can predict failure of local
therapy. We further examined as to which subgroups of patients could benefit from altered fractionation schemes of radiotherapy. In
univariate analysis, high intratumoural angiogenesis, c-erbB overxpression and mutant-p53 nuclear accumulation were significantly
associated with increased relapse rate (P¼0.0002, 0.009 and 0.05, respectively). In multivariate analysis, the microvessel density and
the c-erbB-2 status were independent and significant factors related to local relapse (P¼0.001, t-ratio 3.36 and P¼0.02, t-ratio 2.26,
respectively). Hypofractionated and accelerated radiotherapy supported with amifostine (HypoARC regimen) was significantly more
effective than standard radiotherapy in cases with high cancer cell proliferation index, c-erbB-2 and p53 overexpression. High
angiogenesis, however, was linked with local relapse regardless of the radiotherapy regimen.
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Adjuvant radiotherapy significantly improves the local control
rates even after radical or partial mastectomy in patients with
aggressive tumour features, such as large primary tumours or
extensive node involvement (Forrest et al, 1996; Early Breast
Cancer Trialists Collaborative Group, 1995; Griem et al, 1987;
Velez-Garcia et al, 1992). Although controversial, several large
studies suggested that local control is also important for the overall
survival of patients (Overgaard et al, 1997, 1999; Ragaz et al, 1997;
Clark et al, 1996). As local recurrence after surgery (with or
without chemotherapy) is less than 20% (Mcneil, 1999; Recht et al,
1999), radiotherapy is often omitted (Athas et al, 2000) as it is
difficult to weigh the benefits of reduced cost and patient
inconvenience that result from the elimination of postoperative
radiotherapy against the disadvantages of local recurrence
(Liljegren et al, 1994).
A recent study reported the results of a prospective study on 72
breast cancer patients with features of locally aggressive or
advanced disease treated with surgery, FEC (5-fluorouracil
500mgm
 2, epirubicine 60mgm
 2 and cyclophosphamide
500mgm
 2) chemotherapy and a very accelerated scheme of
hypofractionated radiotherapy supported with high-dose daily
amifostine (Koukourakis et al, 2002a). The whole radiotherapy
dose is given within 12 consecutive radiotherapy fractions (16
days). After a median of 28 months of follow-up (range 18–42
months), we concluded that the regimen is well tolerated with
significantly reduced early radiation sequelae and with late toxicity
(breast, axilla, thoracic wall) at least equal to that observed in
control groups of patients, within the same follow-up time.
Such a regimen is certainly convenient for patients and
radiotherapy departments, as it reduces the overall days of
radiotherapy down to 35% of the days required for a 45-day
conventional fractionation regimen. Nevertheless, the rationale for
applying such an aggressive regimen was also based on a potential
advantage in terms of local control. Hypofractionated radiotherapy
regimen supported with amifostine cytoprotection (HypoARC),
theoretically, could be more effective for tumours for several
reasons described in detail in previous papers (Koukourakis et al,
2002a; Koukourakis and Yannakakis, 2001). Briefly, radiotherapy
acceleration could abrogate the ominous effect of ‘rapid tumour
repopulation’ on the efficacy of radiotherapy. Furthermore, the use
of large radiotherapy fractions could prove more effective in
tumours with low intrinsic radiosensitivity. As hypoxia pushes the
b-value of the a/b ratio to higher levels (Chapman et al, 1975),
hypoxic tumours may be resistant to low dose per fraction used in
standard or hyperfractionated radiotherapy. In that way,
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the other hand, the addition of high-dose amifostine before each
radiotherapy fraction could help in overcoming the severe early
and late toxicity expected from such an aggressive radiotherapy
regimen, which is indeed confirmed in a prospective study
(Koukourakis et al, 2002a). Local relapse analysis, however, did
not show a significant benefit over standard radiotherapy,
although the 1- and 2-year local relapse-free survival (LRFS) was
95 and 84% in the HypoARC group, respectively, vs 84 and 76% in
the standard radiotherapy arm (Koukourakis et al, 2002a).
In the present study, we show that specific molecular features
relevant to rapid tumour repopulation or to intrinsic radio-
sensitivity (i.e. high proliferation index, p53-mutations or c-erbB-2
overexpression) are linked with high local relapse rate following
postoperative radiotherapy, which can be averted by using large
radiotherapy fractions and treatment acceleration. High angiogen-
esis, however, predicts a high rate of local relapse independent of
the radiotherapy scheme.
MATERIALS AND METHODS
From March 1997 to April 1999 at the University Hospital of
Heraklion, 72 high-risk breast cancer patients treated with surgery
and adjuvant FEC chemotherapy were recruited in a large phase II
study in order to assess the toxicity and efficacy of HypoARC as an
adjuvant regimen (Koukourakis et al, 2002a). Inclusion and
exclusion criteria have been previously reported. Briefly, high-risk
breast cancer patients were recruited (T3,4-stage and/or metastatic
disease in more than three lymph nodes), and all patients had a
good performance status with no other major disease. Informed
consent was obtained before inclusion.
The survival of patients treated with adjuvant HypoARC
chemotherapy was compared to that of a matched control group
of 59 breast cancer patients treated with modified radical
mastectomy followed by six cycles of FEC chemotherapy and
conventionally fractionated radiotherapy. These patients were
treated at the same department, during the same period and
fulfilled the criteria used for the recruitment of patients in the
HypoARC study. Patients’ characteristics and tumour stage were
similar in both groups (Table 1). All tumours were of the ductal
type, unifocal and the surgical margins were negative as revealed in
the histopathology report.
Archieval paraffin-embedded material from the primary breast
carcinoma was retrieved from hospitals, where the surgery had
been performed. We managed to collect tissue samples from 31 out
of 72 patients treated with HypoARC and from 40 out of 59
patients treated with conventional radiotherapy (CRT). Failure to
collect additional samples was mainly because of pathological
diagnosis in centres outside the island of Crete and because of
exhausted tissue material (used in other research projects).
Radiotherapy details
The same irradiation technique was used for standard radio-
therapy and HypoARC. Field positioning was performed with the
aid of a simulator following computerised planning. The breast (or
chest wall), axilla and supraclavicular area were treated with a
LINAC 6MV. Tangential fields were used to irradiate the breast or
chest wall and special care was taken during the simulation so that
less than 2cm of thickness of normal lung was included in these
fields. The inner borders were placed 2cm away from the sternal
midline while the outer border followed the middle axillary line.
Supraclavicular and axillary areas were irradiated with an anterior
field, the dose being calculated at 4cm of depth. A booster
posterior field directed to the axilla (dose calculation at 7cm) was
treated immediately following the treatment of the anterior field in
order to compensate for the loss of dose because of increased
depth. The dose administered with this posterior field was 15% of
the dose given with the anterior one. Tangential fields were also
used to deliver a booster dose to the tumour bed, where a 1cm
tissue equivalent material was placed over this area (5–8cm 7–
10cm) in order to increase the dose to the surface. The onset of
radiotherapy was 25–30 days after the delivery of the last cycle of
chemotherapy. Table 2 shows the radiotherapy fractionation used.
Radiobiological analysis has been reported in a previous study
(Koukourakis et al, 2002a).
Administration of amifostine
Tropisetron (10mg i.v., in 50ml NS infused within 5min) was
given as antiemetic premedication. Amifostine (Ethyol
s), 1000mg
diluted in 50ml NS, was rapidly infused within 5min, the patient
being in a supine position, and under continuous monitoring of
blood pressure. No steroids were used unless indicated by severe
vomiting. Radiotherapy was delivered 20min after the amifostine
infusion.
Table 1 Patients’ and tumour characteristics
Parameter HypoARC (31 patients) CRT (40 patients)
Surgery
Mastectomy 10 17
Conservative 21 23
Surgical margins
Negative 31 40
Positive 0 0
Tumor focality
Unifocal 31 40
Multifocal 0 0
T-N stage
T1-N1b iii,iv,2 3 6
T2-N1b i,ii 81 2
T2- N1b iii,iv,2 15 15
T3-N1b,2 5 7
Grade
1,2 11 19
32 2 1
Menopausal status
Pre 10 15
Post 21 25
Table 2 Radiotherapy schedules used in HypoARC and in the control
group
Field
(Gy/fraction )
  (No
fractions)
Physical
dose (Gy)
Overall
treatment
time (days)
HypoARC 16
Chest wall/breast Tang 3.5 41 4
Tang 4 62 4
Total 38
Supraclavicular/axillary a+p 3.5 11 38.5
Tumour bed (boost) Tang 4 28
Total 46
Standard RT 44
Chest wall Tang 2 25 50
Total 50
Tumour bed Tang 2 71 4
Total 64
Supraclavicular/axillary a+p 2 25 50
Tang=tangential fields; a+p=0 anterior and posterior fields.
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A modified streptavidin immunohistochemical technique was used
to assess the expression of different proteins and oncoproteins.
Sections were dewaxed and peroxidase was quenched with
methanol and H2O2 3% for 15min. Microwaving for antigen
retrieval was used (3 4min). The primary antibodies were
applied for 90min. Following washing with TBS, sections were
incubated with a secondary rabbit-anti-mouse antibody (Kwik
Biotinylated Secondary, 0.69A Shandon-Upshaw) for 15min and
washed in TBS. Kwik Streptavidin peroxidase reagent (039A
Shandon-Upshaw) was applied for 15min and sections were again
washed in TBS. The colour was developed by 15min incubation
with DAB solution and sections were weakly counterstained with
haematoxylin. Normal mouse immunoglobulin-G was substituted
for primary antibody as the negative control (same concentration
as the test antibody), while appropriate tissue samples were used
for positive controls.
For the assessment of the proliferation index, the MIB-1 MoAb
(clone PRO224, YLEM, Italy) was used. The percentage of cells
with nuclear reactivity was recorded in all fields and the mean
value was calculated. The median MIB-1 score was used as a cutoff
point to define two groups of tumours with low vs high
proliferation index.
For c-erbB-2 expression, the NCL-CB11 MoAb was used
(Novocastra Laboratories, UK). The percentage of cancer cells
with a clear membrane staining was recorded in all optical fields
and the mean value was calculated. Tissue samples with a mean
value 420% were considered as positive for c-erbB-2 protein
overexpression.
For mutant p53 protein expression, we used the DO7 MoAb
(DAKO, Denmark). The percentage of cancer cells with nuclear
reactivity was recorded in all optical fields and the mean value was
calculated. Tumour samples with a percentage of positive cancer
cells 410% were considered as positive for p53. Using a similar
method of assessment, the nuclear expression of oestrogen and
progesterone receptors was examined by applying the mouse
MoAb clone 1D5 and the clone 1A6 (dilution 1:100; Immunon-
Shandon, USA), respectively. A cutoff point of 10% of reactive cells
was also used for positivity.
For bcl-2 protein expression, the clone 100 MoAb (DAKO,
Denmark) was used. The percentage of cancer cells with strong
cytoplasmic and/or perinuclear expression was recorded in all
optical fields and the mean value was calculated. Tumour samples
with a mean value higher than 10% were considered as positive for
bcl-2 expression.
Assessment of the intratumoural microvessel density
(MVD)
The JC70 monoclonal antibody (DAKO, Denmark) recognising the
CD31 (platelet/endothelial cell adhesion molecule; PECAM-1) was
used for microvessel staining on 2mm paraffin-embedded sections
using the alkaline phosphatase/antialkaline phosphatase (APAAP)
procedure. Sections were dewaxed, rehydrated and predigested
with protease type XXIV for 20min at 37
oC. The JC70 (1:20) was
applied at room temperature for 30min and washed in TBS.
Rabbit-anti-mouse antibody 1 in 50 was applied for 30min,
followed by application of APAAP complex 1 in 1 for 30min. After
washing in TBS, the last two steps were repeated for 10min each.
The colour was developed by 20min incubation with New Fuchsin
solution. Sections from primary tumours were scanned at low
power ( 40 and  100).
The areas of the highest vascularisation were chosen at low
power ( 100) and microvessel counting followed on three chosen
 200 fields of the highest density (hot spots). Microvessels
adjacent to normal breast or around necrotic areas were excluded
from the appraisal. The MVD was the mean of the vessel counts
obtained. The median MVD was used to define two groups of
patients with low vs high MVD. Vessels with a clearly defined
lumen or well-defined linear vessel shape but not single endothelial
cells were taken into account for microvessel counting.
Statistical analysis
Statistical analysis and graphs were performed using the GraphPad
Prism 2.01 package. A Fisher’s exact test or the unpaired two-tailed
t-test was used for testing relations between the categorical
variables, as appropriate. Local relapse and overall curves were
plotted using the method of Kaplan–Meier, and the log-rank test
was used to determine statistical differences between life tables. A
Cox proportional hazard model was used to assess the effects of
patient and tumour variables on overall survival. A P-value of
o0.05 was considered significant.
RESULTS
Results of immunohistochemistry
The results of immunohistochemistry in the two groups of patients
(HypoARC vs CRT) are shown in Table 3. Overall, 35 out of 71
patients had high intratumoural MVD, 24 out of 71 high MIB-1
proliferation index, 17 out of 71 had membrane c-erbB-2 protein
overexpression, 21 out of 71 had nuclear mt-p53 protein
accumulation and 45 out of 71 had positive cytoplasmic bcl-2
expression. Oestrogen and progesterone receptor expression in the
cancer cell nuclei was noted in 42 out of 71 and 21 out of 71
tumours, respectively. The immunohistochemical findings were
well balanced between the two groups, but the bcl-2 expression was
more frequently noted in the group of patients treated with
HypoARC.
Table 3 Results of molecular analysis according to the type of
radiotherapy
Parameter HypoARC (31 patients) CRT (40 patients)
MVD
Low 16 20
High 15 20
MIB-1 index
Low 19 28
High 12 12
c-erbB-2
Negative 21 33
Positive 10 7
mt-p53
Negative 21 29
Positive 10 11
bcl-2
Negative 8 18
Positive 23 22
ER
Negative 12 17
Positive 19 23
PgR
Negative 21 29
Positive 10 11
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Out of 31 patients treated with HypoARC, four (12.9%) relapsed
locally vs seven out of 40 (17.6%) of patients treated with CRT. The
LRFS of patients treated with HypoARC or CRT is plotted in
Figure 1. There was no significant difference between the two
groups (P¼0.59). The type of surgery (mastectomy vs tumour-
ectomy) or the menopausal status was not related to local relapse
(P¼0.40 and 0.96, respectively; data not shown).
Table 4 shows the univariate and multivariate analyses of LRFS
in all patients considered together. In univariate analysis, high
intratumoural angiogenesis, c-erbB overxpression and mutant-p53
nuclear accumulation were significantly associated with increased
relapse rate (P¼0.0002, 0.009 and 0.05, respectively). In multi-
variate analysis, the MVD and the c-erbB-2 status were indepen-
dent and significant factors related to local relapse (P¼0.001, t-
ratio 3.36 and, P¼0.02, t-ratio 2.26, respectively).
Local relapse-free survival LRFS analysis according to the
radiotherapy regimen
The Kaplan–Meier LRFS curves were plotted and the log-rank test
was calculated, using double stratification for the radiotherapy
method and for each one of the assessed histological and molecular
variables.
High MVD was associated with poor LRFS whether patients
were treated with HypoARC or CRT (Figure 2A). On the contrary,
high proliferation MIB-1 index was associated with significantly
poor LRFS in patients treated with CRT (P¼0.007), but not
in patients treated with HypoARC (P¼0.50). Patients with
high proliferation index treated with HypoARC had a signi-
ficantly better LRFS than patients treated with CRT (P¼0.04);
Figure 2B.
Similarly, patients overexpressing c-erbB-2 had a significantly
poorer LRFS when treated with CRT (P¼0.001), while c-erbB-2
Table 4 Univariate and multivariate analyses of local relapse: histological and molecular variables
Univariate Multivariate
P-value Risk ratio 95%CI P-value Risk ratio 95% CI
T-stage T3 vs T1,2 0.13 1.95 0.3–8.4 0.22 1.23 0.4–2.1
N-stage N1biii,iv,2 vs N0,1bi,ii 0.84 1.10 0.3–3.8 0.51 1.41 0.6–2.6
Grade 3 vs 1,2 0.20 1.90 0.5–6.1 0.42 1.25 0.5–2.5
MVD High vs low 0.0002 16.0 11–24 0.001 3.36 2.1–9.8
MIB-1 High vs low 0.11 2.42 0.7–9.2 0.46 1.38 0.5–2.1
c-erbB-2 Positive vs negative 0.009 4.20 1.6–18.7 0.02 2.26 1.5–6.9
mt-p53 Positive vs negative 0.05 3.15 1.0–14 0.12 1.56 0.9–4.8
bcl-2 Negative vs positive 0.18 1.95 0.6–8.1 0.32 0.98 0.4–2.9
ER Negative vs positive 0.32 1.80 0.5–6.2 0.74 0.32 0.1–1.1
PgR Negative vs negative 0.37 1.80 0.4–6.2 0.99 0.01 0–0.1
RT-regimen Hypoarc vs Standard 0.55 0.71 0.2–2.3 0.38 0.36 0.1–1.4
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Figure 1 Kaplan–Meier survival curves stratified for radiotherapy
schedule (conventional vs HypoARC).
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Figure 2 (A) Kaplan–Meier survival curves stratified for radiotherapy
schedule (conventional vs HypoARC) and microvessel density (low vs high).
(B) Kaplan-Meier survival curves stratified for radiotherapy schedule
(conventional vs HypoARC) and MIB1 proliferation index (low vs high). (C)
Kaplan–Meier survival curves stratified for radiotherapy schedule (conven-
tional vs HypoARC) and c-erbB-2 membrane overexpression (negative vs
positive).
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HypoARC. The LRFS of c-erbB-2+ patients treated with HypoARC
was better, although not significantly, than the one of c-erbB-2+
patients treated with CRT (P¼0.13); Figure 2C.
Nuclear expression of mt-p53 was associated with poor LRFS
only in the group of patients treated with CRT (P¼0.002). Patients
with mt-p53+ tumours treated with HypoARC had a better LRFS
than patients with mt-p53+ tumours treated with CRT (P¼0.06).
Analysis of T-stage, N-stage and histology grade did not reveal
any significant differences between the HypoARC and the CRT
efficacy in preventing local relapse. Similarly, HypoARC and CRT
were equally effective within the positive or negative for ER, PgR or
bcl-2 subgroups of patients (data not shown).
Multivariate analysis within the group of patients treated with
CRT revealed that high MVD (P¼0.009, t-ratio 2.76), c-erbB-2
overexpression (P¼0.05, t-ratio 1.98) and mt-p53 expression
(P¼0.05, t-ratio 1.96) were independent variables related to local
relapse. Multivariate analysis within the HypoARC group of
patients showed that only high MVD had an independent
predictive role of local relapse, although of marginal significance
(P¼0.07, t-ratio 1.86).
DISCUSSION
An important role of molecular variables in defing relapse of breast
cancer after local and systemic therapy has been raised during the
past decade. Loss of oestrogen or progesterone receptor expression
was the first molecular feature recognised to associate with poor
survival in breast cancer (Chevallier et al, 1988). C-erbB-2
expression has been linked to resistance to chemotherapy and
poor outcome (Andrulis et al, 1998), while apoptosis-related
proteins such as p53 and bcl-2 have been related to disease-free
interval and survival of breast cancer patients (Thor et al, 1992;
Gasparini et al, 1995). Similarly, a large body of clinicopathological
studies support the important and independent prognostic role of
the tumour angiogenic ability in operable breast cancer (Locopo
et al, 1998). Most of the studies, however, focus on the overall
relapse events, while the impact of molecular variables on the
efficacy of postoperative radiotherapy to control local disease
remains largely unknown.
Nevertheless, several histopathological or patient-related vari-
ables have been reported to define a higher risk of local relapse
after postoperative radiotherapy. In a recent analysis by Katz et al
(2001), in 1031 mastectomised breast cancer patients, disease close
to the surgical margins, gross multifocality, tumour size 45cm
and cancer metastasis in more than three axillary nodes were
independently related to a higher risk of local relapse following
postoperative radiotherapy. Similar results have been reported in
another recent study from Japan, in 301 stage I/II breast-cancer
patients treated with lumpectomy or quadrantectomy (Kodaira
et al, 2001). Young age and less extensive surgery had an
independent predictive role of local relapse, while positive surgical
margins or extensive intraductal component had a marginal
significance. Systemic therapy seems also to contribute to the local
relapse-free interval of breast-cancer patients, as recently shown in
a study of 484 node negative breast cancer patients treated with
breast conservative surgery and radiotherapy (Buchholz et al,
2001).
Our study comprised a relatively limited number of breast
cancer patients. All of them, however, although operable had local
and/or regional extensive disease. This was a result of the inclusion
criteria used for the enrolment of patients in the HypoARC study
(Koukourakis et al, 2002a). All patients had received FEC
chemotherapy before radiotherapy. Clear surgical margins and
unifocal disease was a prerequisite to include a tumour sample in
the present clinicopathological study. Thus, out of the traditional
patient/histology variables, menopausal status and surgical tech-
nique were the only ones left to test as predictors of local relapse.
None of them was significantly related to local relapse in this high-
risk series of patients.
Molecular analysis, however, showed that increased intratu-
moural MVD, c-erbB-2 membrane overexpression, accumulation
of mutant p53 protein and high proliferation index assessed with
the MIB-1 MoAb defines subgroups of patients with increased risk
of local relapse, in high-risk breast cancer patients. In multivariate
analysis, high MVD and c-erbB-2 overexpression retained their
significant and independent predictive role for local relapse, while
p53 and proliferation index did not.
The important role of upregulated angiogenic pathways in the
outcome of radiotherapy has been recently raised (Koukourakis
et al, 2000a,b). It seems that high angiogenic activity confers a
proliferation/apoptosis advantage in cancer cells during radio-
therapy (Matsushita et al, 1999; Natsura et al, 1999), while an
angiogenic regeneration of tumours during radiotherapy cannot be
excluded (Koukourakis et al, 2000b). C-erbB-2 protein over-
expression in breast cancer seems also to relate to resistance to
radiotherapy (Formenti et al, 2002). Treatment of cancer cells with
anti-c-erbB-2 MoAbs before radiotherapy significantly enhances
the cytotoxic effect of radiotherapy, which shows that c-erbB-2
overexpression is involved in biological pathways relevant to the
intrinsic radiosensitivity (Pietras et al, 1999). c-erbB-2 involve-
ment in the upregulation of the VEGF angiogenic pathway (Petit
et al, 1997) suggests that c-erbB-2-related radioresistance is, at
least in part, linked to the tumour angiogenic activity. The
involvement of wild-type p53 protein in the radiation-induced
apoptosis (Brugarolas et al, 1995), at least in part, explains the
finding that mutant p53 expression is related to reduced efficacy of
local radiotherapy. A strong association of nuclear p53 protein
accumulation with local relapse in breast cancer patients receiving
or not postoperative radiotherapy has been recently reported by
Zellars et al (2000). The association of a high proliferation index
with local relapse may be explained by a possible role of rapidly
proliferating cells in the so-called ‘accelerated clonogen repopula-
tion’ phenomenon during radiotherapy (Withers et al, 1998). An
increased rate of locoregional and distant relapse has been
reported in patients with breast cancer bearing a high thymidine
labelling index (Amadori and Silvestrini, 1998).
About half of the cases included in the study were treated with
an accelerated HypoARC. Analysis of local relapse within the
groups of patients treated with CRT and HypoARC radiotherapy
showed a striking difference regarding the influence of the
examined molecular variables. High proliferation index was not
a predictive factor of local relapse in the group of patients treated
with accelerated (HypoARC) radiotherapy. The 2-year LRFS was
100% in the HypoARC group vs 56% in patients treated with CRT.
This shows that radiotherapy acceleration overcomes the ominus
effect of a high cancer cell proliferation rate, which is in
accordance with the concept that accelerated radiotherapy over-
comes the effect of ‘accelerated repopulation’.
Similarly, HypoARC was more effective than CRT in tumours
with p53 mutations. The 2-year LRFS was 100% in the HypoARC
group vs 54% in the CRT group. Loss of wild-type p53 protein
results in failure of radiation-induced DNA damage to trigger
apoptosis events downstream p53 (Brugarolas et al, 1995). Large
radiotherapy fractions that induce a more severe DNA damage
may be more effective in wt-p53-deficient cells, which could
explain the higher efficacy of HypoARC. HypoARC was also more
effective in c-erbB-2 overexpressing tumours. Although a definite
explanation for this finding cannot be provided, acceleration of
radiotherapy may have overcome an eventual growth advantage
conferred by c-erbB-2 upregulation (Mandler et al, 2000). Still,
recent studies suggest that c-erbB-2-is involved in the repair of the
radiation-induced DNA damage as MoAbs against c-erbB-2
enhance radiosensitivity of human breast and head–neck cancer
cells (Pietras et al, 1999; Uno et al, 2001). Hypofractionation could
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intrinsic radioresistance.
An interesting finding was that highly angiogenic tumours were
resistant to radiotherapy, whether conventionally fractionated,
accelerated or hypofractionated. This shows that altered fractiona-
tion or reduced overall treatment time are impossible to counteract
the radioresistance pathways related to tumour angiogenicity.
Antiangiogenic policies are awaited to improve the local control in
patients with highly angiogenic breast cancer. Indeed, several
experimental data suggest an important enhancement of the
efficacy of radiotherapy when combined with various antiangio-
genic agents (Gorski et al, 1999; Mauceri et al, 1998).
In a previous study, we showed that HypoARC is a regimen with
reduced early toxicity and, at least within a median of 28 months of
follow-up, late radiation sequelae were in the range of that
expected from CRT. In the present study, we showed that
HypoARC regimen is not at all equivalent to CRT, in terms of
antitumour activity. It is evident that HypoARC, by using large
radiotherapy fractions while accelerating radiotherapy, targets
subgroups of breast tumours with a high risk to relapse following
CRT. Tumours with a high proliferation index and eventually a
high fraction of clonogens able to enter the phase of accelerated
repopulation during CRT, as well as tumours with increased
intrinsic radioresistance (e.g. mutations of p53 or c-erbB-2 gene
amplification) have about 50% chance to recure after CRT; this
seems to be averted using HypoARC. The ominous impact of
upregulated angiogenic pathways, however, is unlikely to be
prevented by altering the radiotherapy schedules. Antiangiogenic
policies are demanded to improve local control. As HypoARC
seems to overcome both intrinsic radioresistance and accelerated
repopulation, taking also into account the promising low early and
late side effects of the regimen, its role in clinical radiotherapy
should be thoroughly examined. Prostate cancer, recently shown to
have an a/b ratio lower than 2Gy (Fowler et al, 2001), and also
tumours with low intrinsic radiosensitivity (e.g. sarcomas,
melanomas and pancreatic carcinoma) are expected to benefit
from HypoARC regimens. The above findings should, however, be
confirmed in larger studies, once mature data from ongoing
HypoARC studies become available.
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